Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (224)	7/26/2002 12:31:32 AM
From: nigel bates	Respond to of 469

As you wish <g> - EU scientific committee backs OGS's Vevesca LONDON, July 25 (Reuters) - Europe's drug agency on Thursday said its scientific committee had recommended Oxford GlycoSciences Plc 's lead drug, Vevesca, to be used for the treatment of Gaucher disease. Shares in British biotech firm plunged last month after U.S. regulators rejected the drug. But Chief Executive David Ebsworth, who took up his post officially on July 1, told Reuters at the time that he was optimistic Vevesca would still be approved by European regulators in the third quarter of this year, despite the FDA's ruling. He said the firm had been in constant dialogue with European authorities and had provided them with recent data that had not been part of the submission to the FDA. Gaucher disease is a rare illness in which the body struggles to break down fat. The committee's positive opinion means the drug -- which enjoys orphan status in Europe -- should be approved by the EU later this yea...